Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Begelomab vs Conventional Treatment in Steroid-Resistant Acute GvHD
NCT02411084Phase 3Terminated
- Sponsor
- Adienne
- Start
- Feb 2016
- Primary completion
- Jul 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of begelomab in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Adienne. Started Feb 2016; status: terminated.
02
Drugs
begelomab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02411084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02411084.